Connect with us

Biotech

Some companies make money from the coronavirus outbreak

Not all companies have lost money due to the coronavirus outbreak and the historic fall in global markets in recent days. There are firms which, due to the nature of their business, have seen a sudden rise in revenue. Moderna shares went up 42% after the announcement of the shipment of an experimental coronavirus vaccine to the U.S. Regeneron Pharmaceuticals index raised by 10%.

Published

on

This picture show a person holding a hand sanitizer.

The forecasts suggest that if the coronavirus outbreak continues to grow, some companies around the world could further improve their sales and the value of their shares on the stock markets.

These include, of course, companies that manufacture vaccines, disinfectant products, and masks. And within that group, the shares of pharmaceutical and biotechnology companies that are doing clinical trials to develop a specific vaccine against the new coronavirus have skyrocketed.

Find out the latest financial news with the Born2Invest mobile app. News from the biotech industry, crowdfunding sector, and more.

Companies that have benefited indirectly from the spread of the coronavirus

Inovio Pharmaceuticals’ shares increased after the company announced that it would begin clinical trials of a vaccine in humans, next month in the U.S. The company’s value has more than doubled. The other competitors are Moderna, Novavax, Gilead, AIM ImmunoTech and Vir Biotechnology.

But there are other companies that have benefited indirectly from the spread of the coronavirus, such as those dedicated to providing the service of teleconferencing, online education, and entertainment, since some countries, such as Japan and Italy, have closed schools. Some companies, such as Google and Twitter, have asked their employees to work remotely.

In different parts of the world, people are choosing to avoid public places, as the number of infected cases (more than100,000 worldwide) and deaths (more than 4,000) increases, according to the latest report from the World Health Organization.

Precisely to account for this new reality, the investment company MKM Partners created a “Stay at Home Index,” whose objective is to follow the trajectory of companies that have benefited from the spread of the coronavirus.

Companies values more than doubled since the beginning of the epidemic

However, even the “winning” companies with the health crisis are not exempt from sudden ups and downs, as events evolve minute by minute. Not even the Federal Reserve’s (U.S. central bank) half-point cut in interest rates on Tuesday, March 10th, managed to significantly reverse investors’ pessimistic outlook. Amid the uncertainty, the following is a list of companies that have shown a positive trend.

SEE ALSO  CEO Spotlight: Accenture's Pierre Nanterme

Inovio: the value of its actions has more than doubled since the beginning of the epidemic. Its vaccine, called INO-4800, was developed using the virus’ DNA instead of the traditional method that works based on experiments with inactivated viruses.

Moderna’s shares went up 42% when the company announced the shipment of an experimental coronavirus vaccine to the U.S. National Institute of Allergy and Infectious Diseases for clinical trials in humans.

When Novavax reported on the progress of its research for a vaccine, a few weeks ago, its shares immediately went up 20%.

Regeneron Pharmaceuticals, dedicated to the development of a treatment for the coronavirus, was one of the companies in the S&P 500 Wall Street index that had a 10% increase in its stock price last week, while the rest of the stocks fell sharply in what was the worst week for the global markets since the 2008 crisis.

Investors are betting on companies that develop vaccines and services for those who do not want to leave their homes. In a report, the investment firm MKM Partners said it is paying attention to those products or companies that “could potentially benefit in a world of quarantined individuals.”

Hand sanitizer sales soar

The demand for hand disinfectant is increasing in different parts of the world. According to data released on Tuesday, March 10th, by market research firm Kantar, sales of hand sanitizers in the UK recorded a 255% increase in February, compared to the same month last year.

Some pharmacy chains in the country have even implemented a sales limit of two hand sanitizers per purchase. In the U.S., the sales of these products increased by more than 70% in February, according to a report published by the consulting firm Nielsen.

SEE ALSO  Inflationary and insolvency implosion of the bond market

Asian consumers have also been stockpiling personal hygiene products in the wake of the outbreak. The actions of the company 3M, which manufactures masks among other products, have been erratic, despite the fact that the U.S. government announced a new contract with the company. 

__

(Featured image by Anna Earl via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in EL UNIVERSO, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Olivia McCall is passionate about education, women and children’s rights, and the environment. A long-time investor, she covers news about the latest stocks (lately marijuana and tech), IPOs and indices, and is always on the lookout for socially responsible startups. She also writes about the food sector, and has a keen interest on cryptocurrencies.